274 related articles for article (PubMed ID: 23441093)
1. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR;
Pediatr Blood Cancer; 2013 Aug; 60(8):1375-81. PubMed ID: 23441093
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Barhdadi A; Dubé MP; Al-Saloos H; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Brown AM; Rogers PC; Phillips MS; Rieder MJ; Carleton BC; Hayden MR;
J Clin Oncol; 2012 May; 30(13):1422-8. PubMed ID: 21900104
[TBL] [Abstract][Full Text] [Related]
3. Clinical prediction models for anthracycline-associated cardiotoxicity among pediatric cancer survivors--ready for prime time?
Ojha RP; Gurney JG; Green DM
Pediatr Blood Cancer; 2013 Aug; 60(8):1245-6. PubMed ID: 23630170
[No Abstract] [Full Text] [Related]
4. Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients.
Vargas-Neri JL; Carleton B; Ross CJ; Medeiros M; Castañeda-Hernández G; Clark P
Pharmacogenomics; 2022 Apr; 23(5):291-301. PubMed ID: 35147047
[No Abstract] [Full Text] [Related]
5. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy.
Loucks CM; Yan K; Tanoshima R; Ross CJD; Rassekh SR; Carleton BC
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():95-99. PubMed ID: 33900042
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.
Visscher H; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR; Ross CJ;
Pharmacogenomics; 2015; 16(10):1065-76. PubMed ID: 26230641
[TBL] [Abstract][Full Text] [Related]
7. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.
Hertz DL; Caram MV; Kidwell KM; Thibert JN; Gersch C; Seewald NJ; Smerage J; Rubenfire M; Henry NL; Cooney KA; Leja M; Griggs JJ; Rae JM
Pharmacogenomics; 2016 Feb; 17(3):231-40. PubMed ID: 26799497
[TBL] [Abstract][Full Text] [Related]
8. Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.
Garrone O; Crosetto N; Lo Nigro C; Catzeddu T; Vivenza D; Monteverde M; Merlano M; Feola M
Cardiovasc Toxicol; 2012 Jun; 12(2):135-42. PubMed ID: 22189487
[TBL] [Abstract][Full Text] [Related]
9. Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity.
Siemens A; Rassekh SR; Ross CJD; Carleton BC
Ther Drug Monit; 2023 Jun; 45(3):337-344. PubMed ID: 36728273
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-related cardiotoxicity: are Australian practitioners missing the point?
Conyers R; Costello B; La Gerche A; Tripaydonis A; Burns C; Ludlow L; Lange P; Ekert P; Mechinaud F; Cheung M; Martin M; Elliot D
Intern Med J; 2017 Oct; 47(10):1166-1172. PubMed ID: 28485067
[TBL] [Abstract][Full Text] [Related]
11. The Role of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 Single-nucleotide Polymorphisms in the Doxorubicin-induced Cardiotoxicity in Solid Childhood Tumors.
Gündüz A; Duman D; Başbinar Y; Taşdelen B; Küpeli S; Karpuz D
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e65-e70. PubMed ID: 37828659
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
[TBL] [Abstract][Full Text] [Related]
13. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
Aminkeng F; Ross CJ; Rassekh SR; Hwang S; Rieder MJ; Bhavsar AP; Smith A; Sanatani S; Gelmon KA; Bernstein D; Hayden MR; Amstutz U; Carleton BC;
Br J Clin Pharmacol; 2016 Sep; 82(3):683-95. PubMed ID: 27197003
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk.
Linschoten M; Teske AJ; Cramer MJ; van der Wall E; Asselbergs FW
Circ Genom Precis Med; 2018 Jan; 11(1):e001753. PubMed ID: 29557343
[TBL] [Abstract][Full Text] [Related]
16. Exercise training mitigates anthracycline-induced chronic cardiotoxicity in a juvenile rat model.
Hayward R; Lien CY; Jensen BT; Hydock DS; Schneider CM
Pediatr Blood Cancer; 2012 Jul; 59(1):149-54. PubMed ID: 22052855
[TBL] [Abstract][Full Text] [Related]
17. An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.
Dionne F; Aminkeng F; Bhavsar AP; Groeneweg G; Smith A; Visscher H; Rassekh SR; Ross C; Carleton B
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29271558
[TBL] [Abstract][Full Text] [Related]
18. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
[TBL] [Abstract][Full Text] [Related]
19. Roles of pharmacogenomics in non-anthracycline antineoplastic-induced cardiovascular toxicities: A systematic review and meta-analysis of genotypes effect.
Leong SL; Chaiyakunapruk N; Tassaneeyakul W; Arunmanakul P; Nathisuwan S; Lee SWH
Int J Cardiol; 2019 Apr; 280():190-197. PubMed ID: 30594345
[TBL] [Abstract][Full Text] [Related]
20. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy.
Ky B; Carver JR
Heart Fail Clin; 2011 Jul; 7(3):323-31. PubMed ID: 21749884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
